Phibro Animal Health (NASDAQ:PAHC) Raised to “Strong-Buy” at StockNews.com

Phibro Animal Health (NASDAQ:PAHC) was upgraded by equities research analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a report issued on Wednesday.

Other equities analysts have also issued research reports about the stock. Barclays upped their price target on shares of Phibro Animal Health from $13.00 to $20.00 and gave the stock an “underweight” rating in a research report on Tuesday, November 12th. Morgan Stanley increased their target price on Phibro Animal Health from $20.00 to $25.00 and gave the stock an “equal weight” rating in a research report on Tuesday, December 17th. Two analysts have rated the stock with a sell rating, two have given a hold rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $20.50.

Phibro Animal Health Price Performance

PAHC traded down $0.09 during midday trading on Wednesday, reaching $21.90. 99,351 shares of the company’s stock were exchanged, compared to its average volume of 146,231. The business’s 50-day moving average price is $22.08 and its 200 day moving average price is $21.48. The stock has a market capitalization of $887.02 million, a PE ratio of 50.93, a P/E/G ratio of 0.56 and a beta of 0.53. Phibro Animal Health has a 1-year low of $10.03 and a 1-year high of $25.98. The company has a debt-to-equity ratio of 1.81, a current ratio of 3.23 and a quick ratio of 1.69.

Phibro Animal Health (NASDAQ:PAHC) last posted its quarterly earnings data on Wednesday, November 6th. The company reported $0.35 EPS for the quarter, topping analysts’ consensus estimates of $0.23 by $0.12. Phibro Animal Health had a return on equity of 21.59% and a net margin of 1.67%. The firm had revenue of $260.40 million during the quarter, compared to analysts’ expectations of $277.76 million. During the same quarter last year, the business posted $0.14 EPS. As a group, equities analysts anticipate that Phibro Animal Health will post 1.62 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of PAHC. nVerses Capital LLC bought a new position in shares of Phibro Animal Health in the 3rd quarter worth about $70,000. Quantbot Technologies LP bought a new stake in shares of Phibro Animal Health in the 3rd quarter worth approximately $70,000. China Universal Asset Management Co. Ltd. grew its stake in Phibro Animal Health by 63.7% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 3,912 shares of the company’s stock worth $88,000 after buying an additional 1,522 shares during the last quarter. CWM LLC increased its position in Phibro Animal Health by 190.8% in the third quarter. CWM LLC now owns 6,363 shares of the company’s stock worth $143,000 after buying an additional 4,175 shares during the period. Finally, Algert Global LLC bought a new stake in Phibro Animal Health in the second quarter valued at $193,000. Institutional investors own 99.34% of the company’s stock.

About Phibro Animal Health

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.